Drug intelligence / Profile preview

ME-12 OD

Development stage
Unknown
Lead developer
Systopic Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

ME-12 OD is an oral, extended-release multivitamin combination tablet developed by Systopic Laboratories. It contains methylcobalamin (1500 mcg), pyridoxine hydrochloride (20 mg), and folic acid (5 mg). This combination is primarily indicated for the treatment and management of nutritional deficiencies, peripheral neuropathy (including diabetic neuropathy), megaloblastic anemia, and hyperhomocysteinemia. Methylcobalamin supports nerve regeneration and myelin sheath synthesis, pyridoxine hydrochloride enhances neurotransmitter synthesis and amino acid metabolism, and folic acid is essential for DNA synthesis and red blood cell maturation. Together, these neurotropic B-vitamins work synergistically to restore nerve health, reduce neuropathic pain, and support overall cellular metabolism.

Brand names
ME 12 ODME12 ODME-12 ODME-12 OD Tablet ERME12 OD Tablet ERME 12 OD Tablet ER
Other names
folic acid + mecobalamin + pyridoxinefolic acid + mecobalamin + pyridoxine hydrochloridefolic acid + methylcobalamin + pyridoxinefolic acid + methylcobalamin + pyridoxine hydrochloridemecobalamin + pyridoxine + folic acidmethylcobalamin + pyridoxine + folic acid
02

Targets

MTR (Methionine synthase)DHFR (Dihydrofolate reductase)FOLR1 (FRα)PDXK (Pyridoxal kinase)

Beyond the preview

Go deeper on ME-12 OD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME-12 OD.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call